AstraZeneca (AZN) –
-
Form 6-K ASTRAZENECA PLC For: Apr 25
-
AstraZeneca (AZN) shares jump on much stronger Q1 top and bottom line
-
AstraZeneca (AZN) Tops Q1 EPS by 110c; reaffirms guidance
-
AstraZeneca leaps after smashing first-quarter forecasts
-
Q1 2024 results
-
AstraZeneca (AZN) Announces Voydeya Approval in EU as add-on to ravulizumab or eculizumab
-
AstraZeneca (AZN) PT Lowered to $84 at Morgan Stanley
-
Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials
-
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
-
AstraZeneca (AZN) reports imfinzi plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
-
Form 6-K ASTRAZENECA PLC For: Apr 11
-
AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition
-
AstraZeneca (AZN) reports FASENRA approved for treatment of children aged 6 to 11 with severe asthma
-
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
-
Form 6-K ASTRAZENECA PLC For: Apr 11
-
AstraZeneca (AZN) to Raise Annualized Dividend
-
AstraZeneca announces dividend hike ahead of CEO pay vote
-
AstraZeneca's (AZN) ENHERTU approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors
-
Form 6-K ASTRAZENECA PLC For: Apr 08
-
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors
-
AstraZeneca (AZN:LN) (AZN) PT Raised to GBP129.50 at HSBC
-
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
-
Form 6-K ASTRAZENECA PLC For: Apr 05
-
AstraZeneca (AZN) reports Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer
-
AstraZeneca (AZN) call put ratio 1 call to 5.3 puts with a focus on May 62.50 puts
-
Form 6-K ASTRAZENECA PLC For: Apr 02
-
Form 6-K ASTRAZENECA PLC For: Apr 02
-
Form 6-K ASTRAZENECA PLC For: Apr 02
-
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
-
AstraZeneca (AZN) reports Datopotamab deruxtecan BLA accepted in the US
-
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
-
VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH
-
AstraZeneca (AZN) announces Voydeya approved in the US
-
AstraZeneca's (AZN) Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer
-
Sanofi (SNY) and AstraZeneca (AZN) announce Beyfortus approved in Japan for the prevention of RSV disease in infants
-
Form 6-K ASTRAZENECA PLC For: Mar 25
-
ULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)
-
AstraZeneca (AZN) announces Ultomiris approved in the US for NMOSD
-
Form F-3ASR ASTRAZENECA PLC
-
Puma Biotech (PBYI) Provides Update on AstraZeneca (AZN) Litigation
-
Midday movers: Nvidia, Coinbase fall; Unilever rises
-
AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer
-
Form 6-K ASTRAZENECA PLC For: Mar 19
-
Fusion Pharmaceuticals (FUSN) Acquired by AstraZeneca (AZN) for $21/sh Cash + $3 CVR
-
GRAIL Announces Novel Risk Classification Test to Be Used in Lung Cancer Study
-
AstraZeneca to cap out-of-pocket inhaler costs in US, following rival Boehringer's move
-
AstraZeneca (AZN) caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio
-
AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio
-
Form 6-K ASTRAZENECA PLC For: Mar 14
Back to AZN Stock Lookup
